FeesSafety
Pluang+
Home/Explore/US Market Price/Stocks/VRTX
icon
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Vertex Pharmaceuticals Incorporated (VRTX) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Vertex Pharmaceuticals (VRTX) trades at $542.62, down 0.81% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong 2025 results with $12.00B revenue and $3.95B net income, though recent quarterly EPS missed expectations twice. Positive Phase 2b data for its kidney disease drug inaxaplin (Business Wire, 2026-09-22) highlights pipeline progress beyond its dominant cystic fibrosis franchise.
The outlook remains positive given analyst consensus (85.71% Buy ratings) and a $580.20 price target, but risks include pipeline execution and competitive pressures. Revenue growth to $13.0B in 2026 and high profitability support upside, though valuation multiples (P/E 34.92) require sustained execution.
Read full analysis

Key Stats

  • Market Cap
    $137.57B
  • Volume
    960,186
  • Sector
    Health
  • 52W High
    $559.41
  • 52W Low
    $421.03
  • Typical Hold Time
    124 Days
  • Enterprise Value
    $137.75B
  • Div Yield
    -
  • Trading Activity
    0% Sell | 100% Buy
$538.6
52W Low: $421.03
19 Nov 2025
52W High: $559.41
30 Oct 2026

Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $421.03 and a high of $559.41, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Most Recent News

Content is generated by Aura AI

Snail Games to showcase four indie titles at TwitchCon weekend event for early player trials

Snail, Inc. announced it will showcase four games from its indie branch Wandering Wizard at an exclusive event during TwitchCon weekend hosted by Noiz.gg. The lineup includes the already Steam-available Death Party and three upcoming titles: Whispers...

Market News
3 hours ago
Na
Bullish
news icon
Snail Games to showcase four indie titles at TwitchCon weekend event for early player trials

Class action filed against NuScale Power over alleged misleading statements, deadline to join is Jan 11, 2027

The Rosen Law Firm has filed a class action lawsuit against NuScale Power Corporation for allegedly making false and misleading statements about its competitive advantage and revenue prospects between February 27 and September 10, 2026. Investors who...

Market News
4 hours ago
Rosen Law Firm
Bearish
news icon
Class action filed against NuScale Power over alleged misleading statements, deadline to join is Jan 11, 2027

Two IPOs priced this week; Anthropic IPO set to launch with roadshow underway

This week saw two IPOs priced and one biotech IPO postponed. Additionally, two IPOs and three SPACs filed for upcoming offerings. The highlight is the Anthropic IPO, which has set terms and started its roadshow, marking a major upcoming event in the ...

Market News
5 hours ago
Seeking Alpha
Bullish
news icon
Two IPOs priced this week; Anthropic IPO set to launch with roadshow underway
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $137.57B
  • Volume
    960,186
  • Sector
    Health
  • 52W High
    $559.41
  • 52W Low
    $421.03
  • Typical Hold Time
    124 Days
  • Enterprise Value
    $137.75B
  • Div Yield
    -
  • Trading Activity
    0% Sell | 100% Buy
$538.6
52W Low: $421.03
19 Nov 2025
52W High: $559.41
30 Oct 2026

Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $421.03 and a high of $559.41, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!